Optimal interventional treatment for liver cancer: HAIC, TACE or iTACE?
Transcatheter arterial chemoembolization
Liver Cancer
Interventional radiology
Hepatocellular cancer
DOI:
10.1016/j.jimed.2023.03.001
Publication Date:
2023-05-02T21:18:37Z
AUTHORS (6)
ABSTRACT
Primary liver cancer is a common and lethal malignancy in China. Transcatheter arterial chemoembolization (TACE) globally recognized as the preferred treatment modality for non-surgical resection of hepatocellular carcinoma (HCC), while transcatheter infusion (TAI) another effective interventional HCC. In recent years, hepatic chemotherapy (HAIC) has gained increasing attention an application-regulated TAI. Owing to current debate medical community regarding use HAIC TACE HCC, application both approaches should be considered at higher level, with broader perspective more normative aspect. Accordingly, we aimed define rational combination TAI/HAIC (iTACE), which suggests that two interventions are not superior but lead mutually beneficial situation. this review, sought discuss development, specification, application, challenge innovation, debate, union TACE, clinical latest research on iTACE. We introduce new concepts iTACE expect breakthroughs owing combined major tools.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (39)
CITATIONS (7)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....